# A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

> **NCT01291004** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 206 (actual)

## Conditions studied

- Follicle Development
- Ovarian Follicle
- Follicle Count
- Follicle Size
- Oral Contraceptive

## Interventions

- **DRUG:** Desogestrel/ethinyl estradiol and ethinyl estradiol
- **DRUG:** 28-day drospirenone oral contraceptive
- **DRUG:** 28-day levonorgestrel oral contraceptive

## Key facts

- **NCT ID:** NCT01291004
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-31
- **Primary completion:** 2012-03-31
- **Final completion:** 2012-03-31
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291004, "A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01291004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*